P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy, is safe and effective in relapsed or refractory multiple myeloma patients, results from the first three patients enrolled…
News
A new antibody targeting the BCMA protein — called SEA-BCMA — has shown promising effectiveness and safety results in animal models of multiple myeloma, making…
Screening people with a family history of a multiple myeloma precursor would significantly reduce the chance that a person would develop and die of the cancer, a…
Selinexor, the lead oral therapy developed by Karyopharm Therapeutics, received …
Multiple myeloma patients in China may soon have access to an injectable formulation of melphalan, called Evomela, as the China Food and Drug…
As part of its $15 million Immunotherapy Initiative, the Multiple Myeloma Research Foundation (MMRF) recently awarded $7 million in funding to three innovative research…
The European Commission has extended Xgeva‘s (denosumab) approval for the prevention of bone lesions in multiple myeloma patients, Amgen, the medicine’s maker, announced. The…
The combination of Revlimid (lenalidomide) and dexamethasone for the treatment of relapsed or refractory multiple myeloma showed similar benefits in routine clinical practice as it did…
The investigational therapy bb2121, a possible treatment for relapsed or refractory multiple myeloma patients, is advancing in clinical testing under a recently announced partnership…
A new Phase 3 clinical trial called ACCoRd is underway to investigate the benefits of adding Ninlaro (ixazomib) – a proteasome inhibitor – to…
